Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in all‐cause death ( compared with placebo (moderate certainty).
It is very uncertain whether cerebrolysin or Cerebrolysin‐like agents changes non‐death attrition compared with placebo (very low certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with SAEs** compared with placebo (moderate certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).